BASEL, Switzerland, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Windward Bio Group AG (“Windward”) (Nasdaq: WWB), a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, today announced the pricing of its initial public offering of 10,294,117 common shares at a public offering price of $17.00 per share.

瑞士巴塞尔，2026年11月12日（环球电讯社）——Windward Bio Group AG（“Windward”）（纳斯达克股票代码：WWB），一家致力于为患有严重呼吸系统疾病和皮肤病的患者开发超长效抗体药物的临床阶段生物技术公司，今日宣布其首次公开发行10,294,117股普通股的定价为每股17.00美元。

In addition, Windward has granted the underwriters a 30-day option to purchase up to an additional 1,544,117 common shares at the initial public offering price, less the underwriting discounts and commissions. The gross proceeds to Windward from the initial public offering and the concurrent private placement (see below), without giving effect to the underwriters’ option to purchase additional shares and before deducting underwriting discounts and commissions and offering expenses, are expected to be $225.0 million.

此外，Windward已授予承销商一项为期30天的选择权，可按首次公开发行价格扣除承销折扣和佣金后的净额，额外购买最多1,544,117股普通股。在不考虑承销商额外购股权、且未扣除承销折扣、佣金及发行费用的情况下，Windward从首次公开发行及同步进行的私募配售（见下文）中获得的总收益预计为2.25亿美元。

All of the common shares are being offered by Windward..

所有普通股均由 Windward 发售。

In addition to the common shares sold in the initial public offering, Windward announced a concurrent sale of 1,532,691 common shares and pre-funded warrants to purchase 1,408,485 common shares, in each case at the initial public offering price per common share, in a private placement to Sanofi Foreign Participations B.V.

除在首次公开发行中出售的普通股外，Windward 宣布同时以每股普通股的发行价，通过私募方式向 Sanofi Foreign Participations B.V. 出售 1,532,691 股普通股以及用于购买 1,408,485 股普通股的预融资权证。

for an aggregate purchase price of $50.0 million. The sale of the common shares and pre-funded warrants will not be registered under the Securities Act of 1933, as amended (the “Securities Act”)..

总购买价格为5,000万美元。普通股和预付权证的出售不会根据经修订的《1933年证券法》（“证券法”）进行注册。

Windward’s shares are expected to begin trading on the Nasdaq Global Select Market on November 13, 2026 under the symbol “WWB.” The offering is expected to close on November 16, 2026, subject to customary closing conditions.

Windward 的股票预计将于 2026 年 11 月 13 日在纳斯达克全球精选市场开始交易，股票代码为“WWB”。本次发行预计将于 2026 年 11 月 16 日完成，但须满足惯例交割条件。

Jefferies, TD Cowen, Piper Sandler and UBS Investment Bank are acting as joint book-running managers for the offering.

杰富瑞、TD Cowen、Piper Sandler 和瑞银投资银行担任此次发行的联席账簿管理人。

A registration statement relating to the shares being sold in the initial public offering has been filed with the U.S. Securities and Exchange Commission and was declared effective on November 12, 2026. The offering of the shares is being made only by means of a prospectus forming part of the effective registration statement relating to these shares.

与首次公开发行中出售的股份相关的注册声明已提交至美国证券交易委员会，并于2026年11月12日被宣布生效。本次股份的发售仅通过构成该有效注册声明一部分的招股说明书进行。

Copies of the final prospectus, when available, may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at 877-821-7388, or by email at prospectus_department@jefferies.com; TD Securities (USA) LLC, Attn: c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at TDManualrequest@broadridge.com; Piper Sandler & Co., Attention: Prospectus Department, 350 North 5th Street, Suite 1000, Minneapolis, MN 55401, by telephone at (800) 747-3924, or by email at prospectus@psc.com or UBS Securities LLC, Attention: Prospectus Department, 11 Madison Avenue, New York, New York 10010, by email at ol-prospectus-request@ubs.com..

最终招股说明书的副本在备妥后，可从以下机构获取：Jefferies LLC，收件人：股票承销团招股说明书部门，地址：520 Madison Avenue, New York, New York 10022，电话：877-821-7388，电子邮件：prospectus_department@jefferies.com；TD Securities (USA) LLC，收件人：c/o Broadridge Financial Solutions，地址：1155 Long Island Avenue, Edgewood, NY 11717，电子邮件：TDManualrequest@broadridge.com；Piper Sandler & Co.，收件人：招股说明书部门，地址：350 North 5th Street, Suite 1000, Minneapolis, MN 55401，电话：(800) 747-3924，电子邮件：prospectus@psc.com；或 UBS Securities LLC，收件人：招股说明书部门，地址：11 Madison Avenue, New York, New York 10010，电子邮件：ol-prospectus-request@ubs.com。

The concurrent private placement is also scheduled to close on November 16, 2026, subject to the satisfaction of customary closing conditions. The closing of the private placement is contingent and conditioned on consummation of the initial public offering. However, the closing of the initial public offering is not contingent on the consummation of the concurrent private placement..

同步进行的私募配售也计划于2026年11月16日完成，但须满足惯常的交割条件。私募配售的交割以首次公开发行的完成为前提条件。然而，首次公开发行的交割并不以同步私募配售的完成为前提条件。

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction..

本新闻稿不构成出售要约，也不构成购买这些证券的要约邀请；在任何州或司法管辖区，若根据该州或司法管辖区的证券法律，在注册或资格认定之前进行此类要约、邀请或销售属于违法行为，则不得在该州或司法管辖区进行这些证券的任何要约或销售。

For media and investor inquiries:

媒体及投资者问询：

Noel Kurdi

诺埃尔·库尔迪

SVP, Investor Relations and Communications

高级副总裁，投资者关系与传播

investors@windwardbio.com

investors@windwardbio.com